Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.
作者信息
Le Quynh-Thu
机构信息
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
出版信息
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S56-8. doi: 10.1016/j.ijrobp.2007.04.081.
Abstract
摘要
相似文献
1
Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.头颈部癌中缺氧的识别与靶向治疗：当前方法简要概述
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S56-8. doi: 10.1016/j.ijrobp.2007.04.081.
2
Immunohistochemical detection of changes in tumor hypoxia.肿瘤缺氧变化的免疫组织化学检测
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1177-86. doi: 10.1016/j.ijrobp.2008.12.004.
3
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.葡萄糖转运蛋白1（GLUT-1）和碳酸酐酶IX（CAIX）作为子宫颈癌缺氧的内在标志物：与匹莫硝唑结合的关系
Int J Cancer. 2003 Mar 10;104(1):85-91. doi: 10.1002/ijc.10904.
4
Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.微区域水平的肿瘤缺氧：外源性和内源性缺氧细胞标志物的临床相关性及预测价值
Radiother Oncol. 2003 Apr;67(1):3-15. doi: 10.1016/s0167-8140(03)00011-2.
5
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.晚期头颈癌中骨桥蛋白的免疫组织化学检测：预后作用及其与氧电极测量、缺氧诱导因子-1α相关标志物和血红蛋白水平的相关性
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7. doi: 10.1016/j.ijrobp.2006.07.1376. Epub 2006 Oct 23.
6
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.在已知可改变缺氧状态的头颈部鳞状细胞癌放疗中，碳酸酐酶IX（CA IX）缺乏预后和预测价值：DAHANCA 5研究评估
Radiother Oncol. 2007 Jun;83(3):383-8. doi: 10.1016/j.radonc.2007.05.009. Epub 2007 May 31.
7
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.一组组织缺氧标志物在头颈部鳞状细胞癌中的表达及预后意义
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75. doi: 10.1016/j.ijrobp.2007.01.071.
8
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.来自五种缺氧特异性检测的差异风险评估：晚期头颈癌患者生物适应性个体化放疗的基础。
Radiother Oncol. 2007 Jun;83(3):389-97. doi: 10.1016/j.radonc.2007.04.021. Epub 2007 May 17.
9
Hypoxic sensitizer and cytotoxin for head and neck cancer.用于头颈癌的低氧敏化剂和细胞毒素。
Ann Acad Med Singap. 1996 May;25(3):397-404.
10
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.匹莫硝唑结合情况和肿瘤血管生成可预测头颈癌的治疗结果。
Cancer Res. 2002 Dec 1;62(23):7066-74.
引用本文的文献
1
Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients.肿瘤碳酸酐酶IX和Ki-67表达对口腔鳞状细胞癌患者生存的影响。
Oncol Lett. 2017 Nov;14(5):5434-5442. doi: 10.3892/ol.2017.6829. Epub 2017 Aug 25.
2
Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.缺氧对结直肠癌中微小RNA的重塑改变了代谢谱和5-氟尿嘧啶耐药性。
Hum Mol Genet. 2017 Apr 15;26(8):1552-1564. doi: 10.1093/hmg/ddx059.
3
The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.非小细胞肺癌根治性放疗期间肿瘤体积变化与连续血浆骨桥蛋白检测之间的关系
Oncol Lett. 2016 Nov;12(5):3449-3456. doi: 10.3892/ol.2016.5104. Epub 2016 Sep 8.
4
Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.非小细胞肺癌放疗中连续血浆骨桥蛋白测量的预后信息
BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.
5
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.非小细胞肺癌放射治疗中潜在的血浆缺氧标志物的初步研究。骨桥蛋白、碳酸酐酶 IX 和血管内皮生长因子。
Strahlenther Onkol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.
6
Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC).缺氧诱导的自噬反应与头颈部鳞状细胞癌（HNSCC）原位免疫活性小鼠模型中的侵袭表型和转移发生率升高有关。
Exp Mol Pathol. 2011 Apr;90(2):215-25. doi: 10.1016/j.yexmp.2010.11.011. Epub 2011 Jan 12.
7
Osteopontin: an effector and an effect of tumor metastasis.骨桥蛋白：肿瘤转移的效应物和效应子。
Curr Mol Med. 2010 Feb;10(1):71-81. doi: 10.2174/156652410791065381.
8
Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.硝基咪唑化合物和缺氧诱导因子-1在肿瘤缺氧成像中的意义
Cancer Sci. 2009 Aug;100(8):1366-73. doi: 10.1111/j.1349-7006.2009.01195.x. Epub 2009 May 14.
9
Radioprotection.辐射防护
In Vivo. 2009 Mar-Apr;23(2):323-36.
本文引用的文献
1
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.晚期头颈癌中骨桥蛋白的免疫组织化学检测：预后作用及其与氧电极测量、缺氧诱导因子-1α相关标志物和血红蛋白水平的相关性
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7. doi: 10.1016/j.ijrobp.2006.07.1376. Epub 2006 Oct 23.
2
Do erythropoietin receptors on cancer cells explain unexpected clinical findings?癌细胞上的促红细胞生成素受体能否解释意外的临床发现？
J Clin Oncol. 2006 Oct 10;24(29):4708-13. doi: 10.1200/JCO.2006.06.2737.
3
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.顺铂联合5-氟尿嘧啶及放疗加或不加替拉扎明用于可切除的IV期头颈部鳞状细胞癌患者的随机II期试验的成熟结果。
Cancer. 2006 May 1;106(9):1940-9. doi: 10.1002/cncr.21785.
4
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.在CHART随机试验中招募的头颈癌患者中，两种不同缺氧反应途径的内源性标志物（缺氧诱导因子2α和碳酸酐酶9）与放疗失败相关。
J Clin Oncol. 2006 Feb 10;24(5):727-35. doi: 10.1200/JCO.2005.02.7474. Epub 2006 Jan 17.
5
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.血浆骨桥蛋白、缺氧及对头颈部癌放疗中缺氧敏化剂尼莫唑的反应：丹麦头颈癌研究组5随机双盲安慰剂对照试验的结果
Lancet Oncol. 2005 Oct;6(10):757-64. doi: 10.1016/S1470-2045(05)70292-8. Epub 2005 Aug 27.
6
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.397例头颈部肿瘤原发放疗后肿瘤氧合的预后价值：一项国际多中心研究
Radiother Oncol. 2005 Oct;77(1):18-24. doi: 10.1016/j.radonc.2005.06.038. Epub 2005 Aug 10.
7
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.肿瘤血管正常化：抗血管生成治疗中的一个新兴概念。
Science. 2005 Jan 7;307(5706):58-62. doi: 10.1126/science.1104819.
8
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).替拉扎明、顺铂与放疗联用对比氟尿嘧啶、顺铂与放疗用于局部晚期头颈癌患者：跨塔斯曼放射肿瘤学组（TROG 98.02）的一项随机II期试验
J Clin Oncol. 2005 Jan 1;23(1):79-87. doi: 10.1200/JCO.2005.01.072.
9
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.血管内皮生长因子（VEGF）特异性抗体贝伐单抗在人类直肠癌中具有抗血管生成作用的直接证据。
Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25.
10
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.促红细胞生成素治疗接受放疗的头颈癌贫血患者：随机、双盲、安慰剂对照试验
Lancet. 2003 Oct 18;362(9392):1255-60. doi: 10.1016/S0140-6736(03)14567-9.
Zotero 插件